Back to results
US 12,178,940 B2Granted
Controlled hydrogel delivery of focal adhesion kinase inhibitor for decreased scar formation
AssigneeThe Board of Trustees of the Leland Stanford Junior University
InventorsGeoffrey C. Gurtner, Sun Hyung Kwon, Mohammed Inayathullah Nazir Ahmed, Jayakumar Rajadas
Life of this patent
Estimating the term…
Abstract
The formation of scars at a wound site is reduced by contacting the wound site with an effective dose of an inhibitor of focal adhesion kinase (FAK) formulated in a pullulan hydrogel The release profile of the FAK inhibitor can be adjusted according to the nature of the wound, e.g., excisional wounds, burn wounds, etc.
Claims14
A method for promoting tissue healing, comprising:
- placing on a surface of the tissue a composition comprising a porous scaffold and a focal adhesion kinase (FAK) inhibitor fabricated for controlled release disposed in pores of the scaffold;
- and
- delivering to the surface of the tissue a dose of the FAK inhibitor effective to promote tissue healing, scar reduction, and hair growth at a controlled rate during a treatment time,
- wherein the FAK inhibitor is VS-6062 (PF-562271), a benzenesulfonate salt of PF-562271, PF-573228, TAE226 (NVP-TAE226), PF-03814735, PF-562271 HCl, GSK2256098, PF-431396, PND-431396, PND-1186 (VS-4718), Defactinib (VS-6063, PF-04554878), or Solanesol (nonaisoprenol).
1 more element
Dependencies are inferred from the claim text.